Do analysts rate HEPA or CDT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CDT Equity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, HEPA or CDT?

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A CDT Equity N/A N/A -$39.22M -$66.34 thousand N/A

Is HEPA or CDT more profitable?

Hepion Pharmaceuticals' return on equity of -812.56% beat CDT Equity's return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% CDT Equity N/A -4,263.33% -529.91%

Do analysts recommend GLMD or HEPA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GLMD or HEPA?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A

Is GLMD or HEPA more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -29.43% -26.00% Hepion Pharmaceuticals N/A -812.56% -207.31%

Which has higher earnings and valuation, HEPA or CMND?

Clearmind Medicine is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Clearmind Medicine N/A N/A -$3.86M -$139.98 N/A

Is HEPA or CMND more profitable?

Clearmind Medicine's return on equity of -143.79% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Clearmind Medicine N/A -143.79% -88.51%

Do analysts recommend HEPA or PBM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Psyence Biomedical 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, HEPA or PBM?

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Psyence Biomedical N/A N/A $1.01M $25.34 0.12

Is HEPA or PBM more profitable?

Psyence Biomedical's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Psyence Biomedical N/A N/A N/A

Do analysts recommend HEPA or DCOY?

Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 446.45%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Hepion Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hepion Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, HEPA or DCOY?

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hepion Pharmaceuticals N/A N/A -$48.93M -$72.15 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is HEPA or DCOY more profitable?

Decoy Therapeutics' return on equity of -395.42% beat Hepion Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hepion Pharmaceuticals N/A -812.56% -207.31% Decoy Therapeutics N/A -395.42% -193.30%

Hepion Pharmaceuticals (HEPA) Competitors

$0.05 +0.00 (+5.26%)

As of 03:28 PM Eastern

Compare

HEPA vs. CDT, GLMD, CMND, PBM, and DCOY

Should you buy Hepion Pharmaceuticals stock or one of its competitors? MarketBeat compares Hepion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hepion Pharmaceuticals include CDT Equity (CDT), Galmed Pharmaceuticals (GLMD), Clearmind Medicine (CMND), Psyence Biomedical (PBM), and Decoy Therapeutics (DCOY). These companies are all part of the "pharmaceutical products" industry.

How does Hepion Pharmaceuticals compare to CDT Equity?

Hepion Pharmaceuticals (NASDAQ:HEPA) and CDT Equity (NASDAQ:CDT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, CDT Equity had 3 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 3 mentions for CDT Equity and 0 mentions for Hepion Pharmaceuticals. CDT Equity's average media sentiment score of 1.89 beat Hepion Pharmaceuticals' score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
CDT Equity	Very Positive

Hepion Pharmaceuticals' return on equity of -812.56% beat CDT Equity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
CDT Equity	N/A	-4,263.33%	-529.91%

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CDT Equity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
CDT Equity	N/A	N/A	-$39.22M	-$66.34 thousand	N/A

Hepion Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market. Comparatively, CDT Equity has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Summary

CDT Equity beats Hepion Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Galmed Pharmaceuticals?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A

In the previous week, Galmed Pharmaceuticals had 5 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 5 mentions for Galmed Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.35 beat Hepion Pharmaceuticals' score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Neutral
Hepion Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Galmed Pharmaceuticals' return on equity of -29.43% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%

Galmed Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Hepion Pharmaceuticals has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Summary

Galmed Pharmaceuticals beats Hepion Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Clearmind Medicine?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Clearmind Medicine is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Clearmind Medicine	N/A	N/A	-$3.86M	-$139.98	N/A

In the previous week, Clearmind Medicine had 6 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 6 mentions for Clearmind Medicine and 0 mentions for Hepion Pharmaceuticals. Clearmind Medicine's average media sentiment score of 0.67 beat Hepion Pharmaceuticals' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Clearmind Medicine	Positive

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Clearmind Medicine's return on equity of -143.79% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Clearmind Medicine	N/A	-143.79%	-88.51%

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Clearmind Medicine beats Hepion Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Psyence Biomedical?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

In the previous week, Psyence Biomedical had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for Psyence Biomedical and 0 mentions for Hepion Pharmaceuticals. Psyence Biomedical's average media sentiment score of 1.62 beat Hepion Pharmaceuticals' score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Psyence Biomedical	Very Positive

Hepion Pharmaceuticals is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.12

Psyence Biomedical's return on equity of 0.00% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Psyence Biomedical	N/A	N/A	N/A

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 0.1% of Hepion Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Psyence Biomedical beats Hepion Pharmaceuticals on 11 of the 11 factors compared between the two stocks.

How does Hepion Pharmaceuticals compare to Decoy Therapeutics?

Hepion Pharmaceuticals (NASDAQ:HEPA) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 446.45%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Decoy Therapeutics is more favorable than Hepion Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hepion Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Decoy Therapeutics had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for Decoy Therapeutics and 0 mentions for Hepion Pharmaceuticals. Decoy Therapeutics' average media sentiment score of 1.43 beat Hepion Pharmaceuticals' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Hepion Pharmaceuticals	Neutral
Decoy Therapeutics	Positive

Decoy Therapeutics' return on equity of -395.42% beat Hepion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hepion Pharmaceuticals	N/A	-812.56%	-207.31%
Decoy Therapeutics	N/A	-395.42%	-193.30%

Decoy Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hepion Pharmaceuticals	N/A	N/A	-$48.93M	-$72.15	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

Hepion Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 0.1% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Decoy Therapeutics beats Hepion Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Hepion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEPA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HEPA vs. The Competition

Export

Metric	Hepion Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$617K	$979.79M	$6.81B	$12.17B
Dividend Yield	N/A	4.84%	2.68%	5.90%
P/E Ratio	-0.01	1.50	25.79	24.20
Price / Sales	N/A	129.09	548.63	94.36
Price / Cash	N/A	20.06	46.33	53.91
Price / Book	0.04	8.01	10.77	6.37
Net Income	-$48.93M	-$4.05M	$3.57B	$337.69M
7 Day Performance	N/A	0.56%	3.15%	-0.30%
1 Month Performance	N/A	1.25%	2.34%	0.37%
1 Year Performance	N/A	47.34%	33.41%	26.93%

Hepion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HEPA Hepion Pharmaceuticals	N/A	$0.05 +5.3%	N/A	-34.1%	$617K	N/A	N/A	20	Positive News Gap Down
CDT CDT Equity	1.2985 of 5 stars	$0.69 -3.5%	N/A	-99.9%	$3.37M	N/A	N/A	3	News Coverage Positive News Analyst Forecast Gap Down
GLMD Galmed Pharmaceuticals	0.7775 of 5 stars	$0.60 -0.7%	N/A	-68.3%	$3.29M	N/A	N/A	20	Positive News Short Interest Increase
CMND Clearmind Medicine	1.8064 of 5 stars	$3.14 flat	N/A	-99.3%	$3.20M	N/A	N/A	N/A	Short Interest Increase
PBM Psyence Biomedical	1.3255 of 5 stars	$3.09 -2.5%	N/A	-91.2%	$3.16M	N/A	0.12	N/A	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HEPA) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. CDT, GLMD, CMND, PBM, and DCOY

How does Hepion Pharmaceuticals compare to CDT Equity?

Summary

How does Hepion Pharmaceuticals compare to Galmed Pharmaceuticals?

Summary

How does Hepion Pharmaceuticals compare to Clearmind Medicine?

Summary

How does Hepion Pharmaceuticals compare to Psyence Biomedical?

Summary

How does Hepion Pharmaceuticals compare to Decoy Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hepion Pharmaceuticals (HEPA) Competitors

HEPA vs. CDT, GLMD, CMND, PBM, and DCOY

How does Hepion Pharmaceuticals compare to CDT Equity?

Does the media prefer HEPA or CDT?

Is HEPA or CDT more profitable?

Do institutionals and insiders have more ownership in HEPA or CDT?

Do analysts rate HEPA or CDT?

Which has preferable valuation and earnings, HEPA or CDT?

Which has more risk and volatility, HEPA or CDT?

Summary

How does Hepion Pharmaceuticals compare to Galmed Pharmaceuticals?

Which has better valuation & earnings, GLMD or HEPA?

Does the media favor GLMD or HEPA?

Do analysts recommend GLMD or HEPA?

Do institutionals & insiders believe in GLMD or HEPA?

Is GLMD or HEPA more profitable?

Which has more risk and volatility, GLMD or HEPA?

Summary

How does Hepion Pharmaceuticals compare to Clearmind Medicine?

Which has higher earnings and valuation, HEPA or CMND?

Does the media refer more to HEPA or CMND?

Which has more risk & volatility, HEPA or CMND?

Is HEPA or CMND more profitable?

Do insiders & institutionals have more ownership in HEPA or CMND?

Summary

How does Hepion Pharmaceuticals compare to Psyence Biomedical?

Does the media prefer HEPA or PBM?

Which has stronger earnings & valuation, HEPA or PBM?

Is HEPA or PBM more profitable?

Which has more volatility and risk, HEPA or PBM?

Do institutionals & insiders hold more shares of HEPA or PBM?

Do analysts recommend HEPA or PBM?

Summary

How does Hepion Pharmaceuticals compare to Decoy Therapeutics?

Do analysts recommend HEPA or DCOY?

Does the media favor HEPA or DCOY?

Is HEPA or DCOY more profitable?

Which has higher earnings & valuation, HEPA or DCOY?

Which has more volatility & risk, HEPA or DCOY?

Do insiders and institutionals have more ownership in HEPA or DCOY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HEPA vs. The Competition

Hepion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools